Last edition
News about "Patient-Reported Abdominal Fat Rating Scale (PR-AF"
Caliway Cleared by US FDA to Launch Phase 3 Trial of First-in-Class Injectable Fat Reduction Drug
Caliway Biopharmaceuticals has received clearance from the US FDA to initiate SUPREME-01 (CBL-0301)—a pivotal global Phase 3 trial of CBL-514, the first investigational drug aimed at large-area localized fat reduction. This FDA nod marks a key regulatory milestone for Caliway’s global development strategy.
Patient-Reported Abdominal Fat Rating Scale (PR-AF | 29/07/2025 | By Darshana | 441
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy